Physicochemical aspects of doxorubicin-loaded pH-sensitive polymeric micelle formulations from a mixture of poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) [corrected].
In this study, doxorubicin (DOX) was physically incorporated into pH-sensitive micelles made from a mixture of poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) (75/25, wt.%). The DOX-loaded mixed micelles were formulated using dialysis methods and optimal DOX incorporation was achieved at a drug/polymer feed ratio of 0.2 (wt./wt.) when a proper amount of aqueous phase (0.2, v./v.) was added into the common solvent (DMSO) solution, followed by dialysis at 4 degrees C. Based on the results obtained from dynamic light scattering, UV-Vis absorption, and fluorescence experiments, it was demonstrated that the encapsulated drugs were mainly located inside the hydrophobic micelle cores, well protected and inaccessible to the exterior molecules. Under in vitro conditions, although the microstructure of the micelles was altered below pH 8.0 by the encapsulated drugs, the drug-loaded micelles still exhibited a desirable ability to control the drug release in response to tumor extracellular pH.
Yin
Haiqing
H
Department of Pharmaceutics & Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84108, USA.
Bae
You Han
YH
D000903:Antibiotics, Antineoplastic / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003956:Dialysis; D004121:Dimethyl Sulfoxide / Q000737:chemistry; D004317:Doxorubicin / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007773:Lactates / Q000737:chemistry; D008027:Light; D008823:Micelles; D011092:Polyethylene Glycols / Q000737:chemistry; D011506:Proteins / Q000737:chemistry; D012542:Scattering, Radiation; D012997:Solvents / Q000737:chemistry
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D007773:Lactates; D008823:Micelles; D011506:Proteins; D012997:Solvents; C088513:poly(lactic acid-ethylene glycol); C480317:polyhistidine-block-polyethylene glycol; D011092:Polyethylene Glycols; D004317:Doxorubicin; D004121:Dimethyl Sulfoxide
J Control Release. 2008 Mar 3;126(2):130-8
18187224
Eur J Pharm Biopharm. 1999 Sep;48(2):101-11
10469928
J Control Release. 2005 Mar 2;103(1):137-48
15710507
J Drug Target. 2005 Aug;13(7):391-7
16308207
Pharm Res. 1999 Jun;16(6):841-6
10397603
Crit Rev Ther Drug Carrier Syst. 2003;20(5):357-403
14959789
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
17092599
Biophys J. 1976 Jan;16(1):27-41
1244888
Macromol Biosci. 2005 Nov 4;5(11):1118-24
16245269
J Control Release. 2001 May 14;72(1-3):71-84
11389986
Nature. 1998 Apr 30;392(6679 Suppl):5-10
9579855
Cancer Res. 1989 Aug 15;49(16):4373-84
2545340
Prog Biophys Mol Biol. 1978;34(3):175-95
375301
J Control Release. 2003 Jul 31;90(3):363-74
12880703
J Control Release. 2007 Nov 6;123(2):109-15
17894942
J Control Release. 2000 Feb 14;64(1-3):143-53
10640653
Bioconjug Chem. 2005 Mar-Apr;16(2):361-8
15769090
J Control Release. 2005 Mar 21;103(2):405-18
15763623
J Biomater Sci Polym Ed. 2004;15(3):343-56
15147166
Eur J Pharm Biopharm. 2008 Jan;68(1):112-28
17804211
Eur J Pharm Sci. 2006 Oct 1;29(2):120-9
16904301
Curr Med Chem Anticancer Agents. 2005 Jan;5(1):1-13
15720257
J Control Release. 2003 Aug 28;91(1-2):103-13
12932642
Angew Chem Int Ed Engl. 2003 Oct 6;42(38):4640-3
14533151
Adv Drug Deliv Rev. 2002 Oct 16;54(7):1015-39
12384319
J Control Release. 2001 Jun 15;73(2-3):137-72
11516494
J Control Release. 2002 Jan 17;78(1-3):155-63
11772457
Pharm Res. 2007 Jan;24(1):1-16
17109211